Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair (TEAR): A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial.

What was studied

This trial looked at adults with a brain aneurysm that had not burst. Clots can form when doctors repair these from inside the vessel. The team tested a drug called tirofiban at 2 stroke centers in China. People aged 18 to 80 were put by chance into 2 groups. One group got tirofiban into a vein plus 2 anti-clot drugs. The other group got the 2 anti-clot drugs alone.

What they found

Results came from 191 people: 95 got tirofiban and 96 did not. Brain scans were done within 48 hours of the repair. New damaged brain areas were smaller in total with tirofiban. The median size was 48.6 versus 88.2 mm3. The number of new damaged areas also tended to be lower. Stroke with symptoms did not differ clearly between groups. Bleeding also did not differ clearly. This held at 48 hours and at 30 days.

What it means for patients

The authors say tirofiban with 2 anti-clot drugs cut new brain damage after repair. They say it did not raise bleeding problems or deaths. This was seen in people whose aneurysm had not burst.

Why it is not certain yet

This was a phase 2 trial, which is an early step. It took place at only 2 centers in China. People and doctors knew which group each person was in. But the people who read the scans did not know. The authors say a larger trial at many centers must confirm this. The abstract does not give results beyond 30 days.

Source

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair (TEAR): A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.